Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference11 articles.
1. Roche Pharmaceuticals (2007) Package insert. Xeloda (capecitabine). MoH approved leaflets July 2007
2. Common Terminology Criteria for Adverse Events (CTCAE) version 3 (2003) In: Investigator’s Handbook: a manual for participants in clinical trials of investigational agents sponsored by the Division of Cancer Treatment, National Cancer Institute, NIH, 2003
3. Kurt M, Babaoglu MO, Yasar U, Shorbagi A, Guler N (2006) Capecitabine-induced severe hypertriglyceridemia: report of two cases. Ann Pharmacother 40:328–331
4. Koutras AK, Habeos IG, Vagenakis AG, Kalofonos HP (2006) Capecitabine-induced hypertriglyceridemia: a report of two cases. Anticancer Res 26:2249–2252
5. National Cholesterol Education Program (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adults treatment panel III). JAMA 285:2486–2497
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献